Screener
Cytek Biosciences, Inc. CTKB Q3 2026 earnings
Reported November 4, 2026 · After market close
Revenue$53.2MBeat by $181.8K
EPS-$0.05Beat by $0.02
Revenue estimate$53.0M
EPS estimate-$0.07
“We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business. Demand for our high-end instruments remained strong, with high-end Full Spectrum Profiling instrument revenue up 11% and Aurora Evo placements nearly doubling year over year. We also expanded gross margin by nearly 600 basis points. Looking ahead, we are reiterating the midpoint of our full-year revenue guidance and expect a strong finish to the year. We are well positioned to keep gaining market share, with our new product launches continuing to strengthen our technology leadership.”
Next report
Date not yet announcedValuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Cytek Biosciences, Inc. report Q3 2026 earnings?
- Cytek Biosciences, Inc. (CTKB) reported Q3 2026 earnings on November 4, 2026 after market close.
- What were Cytek Biosciences, Inc.'s Q3 2026 revenue and EPS?
- Cytek Biosciences, Inc. reported revenue of $53.2M and eps of $-0.05 for Q3 2026.
- Did Cytek Biosciences, Inc. beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $53.0M by $181.8K. EPS beat the consensus estimate of $-0.07 by $0.02.
- How did Cytek Biosciences, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 1.8% from $52.3M a year earlier and eps declined 400.0% from $-0.01.
- Where can I find Cytek Biosciences, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-447300) and the 10-Q periodic report (0001628280-26-070259) directly on SEC EDGAR. The filing index links above go to sec.gov.
